Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia

Cancer Biomarkers : Section a of Disease Markers
Asmaa M ZahranHelal F Hetta

Abstract

The bone marrow immunosuppressive microenvironment of AML patients sustains and modulates proliferation, survival and drug resistance of AML through deregulation of both innate and adaptive immune response. We aimed to investigate the level of Tregs, expression of Tim-3 on peripheral blood T cells, expression of CD200 in myeloid blasts in newly diagnosed AML patients with normal cytogenetics (AML-NC) and their prognostic impact. This study included 40 patients with de novo AML-NC and 20 healthy controls. Flow-cytometry was used for detection of CD4+CD25+high FoxP3+ regulatory T cells, Tim-3 expression on peripheral blood T cells and CD200 expression on myeloid blasts. The percentages of CD4+CD25+high and CD4+CD25+high Foxp3+ Tregs were significantly increased in AML patients than controls. The levels of Tregs, Tim-3/CD4+, Tim-3/CD8+, CD200 and MFI of CD200 were significantly lower in responding patients than in those with persistent leukemia. Only high CD200 expression (> 50%) showed statistically significant worse OS with P< 0.04. The increased levels of Tregs, Tim-3 expression on peripheral blood T cells and CD200 expression in myeloid blast in AML patients could play a role in the development of AML. Analysis of these marker...Continue Reading

References

Jun 20, 2002·Trends in Immunology·A Neil BarclayMarion H Brown
Nov 16, 2005·Nature Immunology·Chen ZhuVijay K Kuchroo
Jan 26, 2007·Leukemia·A TonksR L Darley
Oct 8, 2008·Leukemia Research·Christian P PallaschClemens-Martin Wendtner
May 7, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Miroslaw J SzczepanskiMichael Boyiadzis
Jun 6, 2009·Journal of Hematology & Oncology·Tara K GregoryWilliam Tse
Jun 19, 2010·Blood·Jacob M Rowe, Martin S Tallman
Oct 20, 2010·Expert Opinion on Biological Therapy·Eyad ElkordDavid E Gilham
Dec 25, 2010·European Journal of Immunology·Kazuki SakaiTaira Maekawa
Sep 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Evan J Lipson, Charles G Drake
Oct 20, 2011·Cancer Research·Shin Foong NgiowMark J Smyth
Dec 20, 2011·American Journal of Clinical Pathology·Daisy AlapatRobert B Lorsbach
Nov 28, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ali MemarianMahmood Jeddi-Tehrani
Apr 2, 2013·Journal of Theoretical Biology·Kang-Ling LiaoAvner Friedman
May 15, 2013·Journal of Leukocyte Biology·Margaret K Callahan, Jedd D Wolchok
Dec 20, 2013·Journal for Immunotherapy of Cancer·Ryan M Teague, Justin Kline
May 6, 2014·Cancer Immunology Research·Ana C Anderson
Jun 21, 2014·Blood·Cliona M Rooney
Sep 18, 2014·Expert Review of Hematology·Alessandro IsidoriAntonio Curti
Mar 10, 2016·Journal of Clinical Medicine·Jennifer N Saultz, Ramiro Garzon

❮ Previous
Next ❯

Citations

Jun 6, 2019·Nanomedicine·Noura H Abd EllahHelal F Hetta
Mar 5, 2020·Oncogene·Zhuoyan LiP Brent Ferrell
Mar 19, 2020·Frontiers in Oncology·Rebecca EpperlyM Paulina Velasquez
Jun 27, 2019·Expert Opinion on Therapeutic Patents·Irma Herrera-CamachoGerardo Landeta
Feb 11, 2021·International Journal of Molecular Sciences·Katarzyna Kotwica-MojzychMariusz Mojzych
Feb 1, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Wen-Jun ZhangHong-Liang Luo
Oct 19, 2021·Frontiers in Oncology·Mahnaz RezaeiMazdak Ganjalikhani-Hakemi

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.